{
    "clinical_study": {
        "@rank": "110981", 
        "arm_group": [
            {
                "arm_group_label": "Lixisenatide + Biguanide", 
                "arm_group_type": "Experimental", 
                "description": "52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)"
            }, 
            {
                "arm_group_label": "Lixisenatide + TZD", 
                "arm_group_type": "Experimental", 
                "description": "52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)"
            }, 
            {
                "arm_group_label": "Lixisenatide + alpha-GI", 
                "arm_group_type": "Experimental", 
                "description": "52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)"
            }, 
            {
                "arm_group_label": "Lixisenatide + Glinide", 
                "arm_group_type": "Experimental", 
                "description": "52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      The primary objective of this study is to assess the overall safety of lixisenatide once\n      daily treatment in combination with background oral anti-diabetic treatment over 52 weeks in\n      patients with type 2 diabetes in Japan.\n\n      Secondary Objective:\n\n      To assess the effects of lixisenatide in combination with background oral antidiabetic drug\n      (OAD) on:\n\n        -  HbA1c;\n\n        -  Fasting plasma glucose;\n\n        -  Body weight."
        }, 
        "brief_title": "Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "54 weeks +/-11 days"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Patients with type 2 diabetes mellitus diagnosed at least 1 year before the screening\n             visit\n\n          -  Patient treated for at least 3 months prior to screening visit with one of following\n             OADs at a stable dose of at least usual maintenance dose as described in the label\n\n               -  a biguanide (metformin hydrochloride);\n\n               -  a thiazolidinedione (TZD) (pioglitazone hydrochloride);\n\n               -  an alpha-glucosidase inhibitor (alpha-GI) (acarbose, voglibose or miglitol);\n\n               -  or a glinide (nateglinide, repaglinide or mitiglinide);\n\n          -  Signed written informed consent\n\n        Exclusion criteria:\n\n          -  At screening HbA1c <7% or >9.5%;\n\n          -  At screening: fasting plasma glucose >250 mg/dL (>13.9 mmol/L);\n\n          -  Use of any glucose-lowering agent(s) other than the authorized patient's background\n             treatment defined in I02 (as given in inclusion critieria) within 3 months prior to\n             screening;\n\n          -  Type 1 diabetes mellitus;\n\n          -  Women of childbearing potential with no effective contraceptive method;\n\n          -  Pregnancy or lactation;\n\n          -  Laboratory findings at the time of screening:\n\n               -  Amylase and/or lipase >3 times the upper limit of the normal laboratory range\n                  (ULN);\n\n               -  ALT >3 ULN;\n\n          -  Any contra-indication to the patient's background oral anti-diabetic treatment;\n\n          -  History of acute or chronic pancreatitis, pancreatectomy, stomach/gastric surgery,\n             inflammatory bowel disease;\n\n          -  Personal or immediate family history of medullary thyroid cancer (MTC) or genetic\n             conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes);\n\n          -  Any previous treatment with lixisenatide (eg, participation in a previous study with\n             lixisenatide) or any other GLP1 receptor agonist.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "292", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940965", 
            "org_study_id": "LTS12809", 
            "secondary_id": "U1111-1129-8754"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lixisenatide + TZD", 
                    "Lixisenatide + Glinide", 
                    "Lixisenatide + alpha-GI", 
                    "Lixisenatide + Biguanide"
                ], 
                "description": "Pharmaceutical form:solution Route of administration: Subcutaneous injection", 
                "intervention_name": "lixisenatide AVE0010", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lixisenatide + Biguanide", 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "biguanide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lixisenatide + TZD", 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "TZD", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lixisenatide + alpha-GI", 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "alpha-GI", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lixisenatide + Glinide", 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "glinide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hypoglycemic Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Adachi-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392335"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiba-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392325"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiyoda-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392328"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392327"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392326"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuoh-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392310"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kagoshima-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392336"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kamakura-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392314"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kashiwara-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392334"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawagoe-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392304"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawaguchi-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392306"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kisarazu-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392307"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koriyama-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392301"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mitaka-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392312"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mito-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392324"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mito-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392302"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392332"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392331"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ohta-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392329"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Okawa-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392322"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392333"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sagamihara-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392330"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saijo-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392320"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sakado-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392303"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392311"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shizuoka-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392316"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392319"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety over 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940965"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Absolute change in HbA1c", 
                "safety_issue": "No", 
                "time_frame": "From baseline to weeks 24 and 52"
            }, 
            {
                "measure": "Absolute change in fasting plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "From baseline to weeks 24 and 52"
            }, 
            {
                "measure": "Absolute change in body weight", 
                "safety_issue": "No", 
                "time_frame": "From baseline to weeks 24 and 52"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}